Enlivex Therapeutics Ltd. will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress in West Palm Beach, Florida, featuring 3‑month and 6‑month efficacy data from its Phase IIa trial (NCT06233474) of Allocetra in patients with moderate‑to‑severe knee osteoarthritis.
The poster sessions are scheduled for April 24‑25, 2026, between 3:30 PM and 4:15 PM ET. The data will be presented by Professor Philip Conaghan, director of the NIHR Leeds Biomedical Research Centre and a leading rheumatologist.
The trial enrolled patients aged 60 years and older, a group that represents more than half of the knee osteoarthritis market. This presentation marks the first public disclosure of these Phase IIa results beyond the data previously released in November 2025, and it is a key milestone in advancing Allocetra toward regulatory approval and potential partnership opportunities.
Enlivex’s dual strategy combines therapeutic development with a prediction‑markets treasury, and the company has recently secured regulatory approvals for its Phase 2b trial in the United States and Denmark. The upcoming presentation underscores the company’s progress in a disease area with significant unmet need and a large, aging population.
The presentation will provide detailed efficacy and mechanistic insights that could strengthen Enlivex’s case for further development and commercial collaboration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.